2024-513142-11-00CompletedPhase 1
Phase Ib Randomised, Placebo-controlled, Double-blind, Multicentre Study to Assess the Effects and Safety of AZD5462 on top of Dapagliflozin in Participants with Heart Failure and Moderate Renal Impairment
Source: EU CTIS (euclinicaltrials.eu) · Last updated 9 Apr 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- First submitted
- 10 Jun 2024
- Start date
- 27 Sept 2024
- Lead sponsor
- AstraZeneca AB
- Diseases
- Heart failure
- EU CT number
- 2024-513142-11-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 56
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical Center Comac Medical Ltd. | Sofia | Bulgaria | Completed |
| Ribocure Pharmaceuticals AB | Molndal | Sweden | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.